project id: TCGA-PRAD; case submitter id: TCGA-EJ-A8FP; analyte type: DNA; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.88; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.4; rna integrity number: 7.7; age at index: 59; days to birth: -21769; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1954; age at diagnosis: 21769; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 299.0; icd 10 code: C61; last known disease status: not reported; morphology: 8500/3; primary diagnosis: Infiltrating duct carcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 145; initial weight: 340.0; sample id: 7862fb6e-85d1-4bf3-a0d9-909e558f85be; sample submitter id: TCGA-EJ-A8FP-01A; portion id: 56e5e1e5-1984-47a4-be5c-09fa5d2bb8b4; portion submitter id: TCGA-EJ-A8FP-01A-21; slide id: 370670de-27cf-4530-b684-797ac0e49dc2; slide submitter id: TCGA-EJ-A8FP-01A-02-TSB; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 30.0; percent stromal cells: 30.0; percent tumor cells: 40.0; percent tumor nuclei: 70.0; section location: TOP;